Shock Syndromes II
Circulation.
2011;123(16):1788-1830.
https://doi.
org/10.1161/cir.0b013e318214914f
Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic
therapy for VTE disease: Antithrombotic Therapy and
Prevention of Thrombosis, 9th ed: American College
of Chest Physicians Evidence-Based Clinical Practice
Guidelines. Chest. 2012;141(2 suppl):e419S-e496S.
https://doi.org/10.1378/chest.11-2301
Kerbaul F, Rondelet B, Motte S, et al. Effects of norepi-
nephrine and dobutamine on pressure load-induced right
https://doi.org/10.1097/01.ccm.0000120052.77953.07
Kerber RE, Gascho JA, Litchfield R, Wolfson P, Ott
D, Pandian NG. Hemodynamic effects of volume
expansion and nitroprusside compared with pericardio-
centesis in patients with acute cardiac tamponade. N Engl
J Med. 1982;307(15):929-931. https://doi.org/10.1056/
nejm198210073071506
Kiser TH, Burnham EL, Clark B, et al. Half-dose versus
full-dose alteplase for treatment of pulmonary embo-
org/10.1097/ccm.0000000000003288
Konstantinides S. Clinical practice. Acute pulmonary
embolism. N Engl J Med. 2008;359(26):2804-2813.
https://doi.org/10.1056/nejmcp0804570
Konstantinides SV, Barco S, Lankeit M, Meyer G.
Management of pulmonary embolism: an update.
J Am Coll Cardiol. 2016;67(8):976-990. https://doi.
org/10.1016/j.jacc.2015.11.061
Konstantinides SV, Meyer G, Becattini C, et al. 2019
ESC guidelines for the diagnosis and management of
acute pulmonary embolism developed in collabora-
tion with the European Respiratory Society (ERS). Eur
Heart J. 2020;41(4):543-603. https://doi.org/10.1093/
eurheartj/ehz405
Konstantinides SV, Vicaut E, Danays T, et al. Impact
of thrombolytic therapy on the long-term outcome of
intermediate-risk pulmonary embolism. J Am Coll
Cardiol. 2017;69(12):1536-1544. https://doi.org/10.1016/j.
jacc.2016.12.039
Kucher N, Goldhaber SZ. Management of massive pul-
monary embolism. Circulation. 2005;112(2):e28-e32.
https://doi.org/10.1161/circulationaha.105.551374
Maisch B, SeferoviΔ PM, RistiΔ AD, et al. Guidelines
on the diagnosis and management of pericardial diseases
executive summary; the Task Force on the Diagnosis and
Management of Pericardial Diseases of the European
Society of Cardiology. Eur Heart J. 2004;25(7):587-610.
https://doi.org/10.1016/j.ehj.2004.02.002
Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for
patients with intermediate-risk pulmonary embolism.
N Engl J Med. 2014;370(15):1402-1411. https://doi.
org/10.1056/nejmoa1302097
Mostafa A, Briasoulis A, Telila T, Belgrave K, Grines
C. Treatment of massive or submassive acute pulmonary
Cardiol. 2016;117(6):1014-1020. https://doi.org/10.1016/j.
amjcard.2015.12.041
SpΓΆhr F, Arntz HR, Bluhmki E, et al. International
multicentre trial protocol to assess the efficacy and
safety of tenecteplase during cardiopulmonary resus-
citation in patients with out-of-hospital cardiac arrest:
the Thrombolysis in Cardiac Arrest (TROICA) study.
Eur J Clin Invest. 2005;35(5):315-323. https://doi.
org/10.1111/j.1365-2362.2005.01491.x
Stein PD, Matta F. Thrombolytic therapy in unstable
patients with acute pulmonary embolism: saves lives but
org/10.1016/j.amjmed.2011.10.015
Stevens SM, Woller SC, Kreuziger LB, et al.
Antithrombotic therapy for VTE disease: second update
of the CHEST Guideline and Expert Panel Report.
Chest. 2021;160(6):e545-e608. https://doi.org/10.1016/j.
chest.2021.07.055
Todd JL, Tapson VF. Thrombolytic therapy for
acute pulmonary embolism: a critical appraisal.
Chest. 2009;135(5):1321-1329. https://doi.org/10.1378/
chest.08-2125
Wan S, Quinlan DJ, Agnelli G, Eikelboom JW.
Thrombolysis
compared
with
heparin
for
the
initial treatment of pulmonary embolism: a meta-
analysis
of
the
randomized
controlled
trials.
Circulation.
2004;110(6):744-749.
https://doi.
org/10.1161/01.cir.0000137826.09715.9c
Stevens-Johnson Syndrome and Toxic Epidermal
Necrolysis
Araki Y, Sotozono C, Inatomi T, et al. Successful treatment
of Stevens-Johnson syndrome with steroid pulse therapy